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Phenotypic characterization of congenital platelet defects (CPDs) could help physi-
cians recognize CPD subtypes and can inform on prognostic implications. We report
the analyses of the bleeding phenotype and diagnostic characteristics of a large
cohort of adult patients with a confirmed CPD. A total of 96 patients were analyzed
and they were classified as Glanzmann thrombasthenia, Bernard-Soulier syndrome,
dense granule deficiency, defects in the ADP or thromboxane A2 (TxA2) pathway,
isolated thrombocytopenia or complex abnormalities. The median ISTH-BAT bleeding
score was nine (IQR 5-13). Heavy menstrual bleeding (HMB) (80%), post-partum
hemorrhage (74%), post-operative bleeds (64%) and post-dental extraction bleeds
(57%) occurred most frequently. Rare bleeding symptoms were bleeds from the uri-
nary tract (4%) and central nervous system (CNS) bleeds (2%). Domains with a large
proportion of severe bleeds were CNS bleeding, HMB and post-dental extraction
bleeding. Glanzmann thrombasthenia and female sex were associated with a more
severe bleeding phenotype.
1 | INTRODUCTION
Congenital platelet disorders (CPDs) are rare bleeding disorders cau-
sed by congenital defects in platelet production or platelet function.
Patients typically present with a mucocutaneous bleeding tendency.
Common symptoms include epistaxis, unexplained or extensive bruis-
ing, oral cavity bleeds, heavy menstrual bleeding (HMB) and bleeding
following a hemostatic challenge such as surgery, dental extraction
and childbirth.1 So, CPDs are clinically heterogeneous; the frequency
and severity of symptoms vary greatly among different types of CPDs,
among patients with the same disorder and within patients over
time.2
The bleeding phenotype can be evaluated with the ISTH Bleeding
Assessment Tool (ISTH-BAT). The ISTH-BAT was designed to
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underscore the importance of repetitive minor bleeding in addition to
more severe bleeds and can be used in all hemorrhagic disorders.3
The ISTH-BAT is primarily designed as a screening tool. Since the
ISTH-BAT documents large variety of bleeding symptoms, it is also
used for the phenotyping of patients.4,5
Very few studies have reported the bleeding phenotype in adult
patients with CPDs6 and most studies focused on a few specific types
of CPD7,8 or a specific mutation.9,10 Phenotypic characterization of
the whole spectrum of CPDs is necessary, since this could help physi-
cians recognize CPD subtypes and inform new patients on prognostic
implications regarding their bleeding phenotype. In this study, we
aimed to evaluate the bleeding phenotype of a large cohort of adult
patients with CPDs and to search for correlations between the bleed-
ing score and different laboratory phenotypes of CPDs.
2 | METHODS
2.1 | Participant selection
Data were derived from patients included in the “Thrombocytopathy
in the Netherlands” (TiN) study; a nationwide cross-sectional study
to collect data on clinical features, functional assays and genetics in
a population of patients with or suspected for a CPD. Patients
were included in the TiN study when von Willebrand disease or a
coagulation factor deficiency were excluded and when they were
previously diagnosed with a CPD, they had previously abnormal
platelet count or function test results, or they exhibited a predomi-
nantly mucocutaneous bleeding tendency compatible with a plate-
let function disorder. Within the TiN study, a CPD was confirmed
when abnormal platelet count or function was found on at least
two occasions, of which one was in our diagnostic laboratory. For
the current evaluation, we included only TiN patients in whom a
CPD diagnosis was confirmed.
2.2 | Bleeding phenotype
The ISTH-BAT was used for evaluation of the patients' bleeding
symptoms and was administered by an experienced physician prior to
platelet function testing. It contains questions on 14 domains: epi-
staxis, cutaneous bleeding, bleeding from minor wounds, urinary tract
bleeding, gastrointestinal bleeding, oral cavity bleeding, post-dental
extraction bleeding, post-operative bleeding, heavy menstrual bleed-
ing (HMB), post-partum hemorrhage (PPH), muscle hematomas, hema-
rthrosis, central nervous system (CNS) bleeding and one final domain
on other bleeding symptoms. Each domain was scored on a scale
ranging from zero to four points. We classified a bleeding symptom as
severe when the domain score was three or higher, since this indi-
cates that the bleeding symptom required medical treatment. The
total of all domains resulted in a bleeding score ranging from 0-56.
The cut-off values for an abnormal bleeding score are >3 for men
and > 5 for women.11
2.3 | Laboratory assessment
Laboratory tests were performed for platelet count, aggregation in
response to four agonists (ADP, arachidonic acid, collagen, ristocetin),
platelet ADP and ATP content, surface receptor expression with flow
cytometry and whole-exome sequencing (WES) with a selected 76-gene
panel (Table S1). Platelet morphology, gray platelets and leukocyte inclu-
sion bodies were assessed in a peripheral blood smear. The cut-off value
for abnormal platelet aggregation was determined for every agonist and
was based on the 2.5th percentile, plus the coefficient of variation of 52
healthy donors (Table S2). The cut-off value for abnormal platelet recep-
tor expression was determined based on the 2.5th percentile of 49
healthy donors (Table S3). Dense granule deficiency was diagnosed when
the ADP content was lower than 1.4 μmol/1011 platelets, based on the
2.5th percentile of 49 healthy donors. In line with the American College
of Medical Genetics guidelines, a genetic variant was stated to be causal
when a (likely) pathogenic variant (class four or five, respectively)12 was
identified in one or more of the selected genes that corresponded to the
platelet phenotype.
2.4 | Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics 25, Gra-
phPad Prism software version 6 and RStudio version 0.99. Descriptive
results for continuous variables were presented as medians (IQR), and
categorical variables were presented as frequencies (percentages). The
difference in bleeding score between types of CPDs, and between men
and women was evaluated with linear regression analysis. Correlations
between bleeding score and number of abnormal agonists in light trans-
mission aggregometry (LTA), and between bleeding score and ADP con-
tent were calculated with non-parametric Spearman's rank correlation.
Correlation coefficients (ρ) of 0.20-0.39 were considered weak, 0.40-
0.59 moderate, 0.60-0.79 strong and >0.8 very strong.13 Only moderate
or stronger correlations were considered relevant.
3 | RESULTS
A CPD diagnosis was confirmed in 96 TiN patients. The majority of
patients were women (61/96, 64%) (Table 1). The median age was
38 years (IQR 28-53) for women and 40 years (IQR 26-57) for men.
The median bleeding score was 9 (IQR 7-15) for women and 6 (IQR 3-
12) for men.
3.1 | Classification of patients based on diagnostic
characteristics
3.1.1 | Glanzmann thrombasthenia
Glanzmann thrombasthenia (GT) was diagnosed in 14 patients based
on decreased or absent aggregation in response to ADP, arachidonic
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acid and collagen and decreased αIIbβ3 expression. The median bleed-
ing score was 21 (IQR 16-22) (Figure 1). The median platelet count
was 183 × 109/L (IQR 133-226) and in 5/14 patients the platelet
count was below the normal range. The median αIIbβ3 expression was
1.9% (IQR 1.4% - 3.3%). Eleven patients had type 1 GT, one patient
had type 2 GT and two patients had variant type GT. Genetic muta-
tions were identified in all 14 patients.
3.1.2 | Bernard-Soulier syndrome
Bernard-Soulier syndrome (BSS) was diagnosed in four patients based
on a decreased aggregation in response to ristocetin and decreased
GP1b-V-IX expression. The median bleeding score was nine (IQR 1-
15). All patients had macrothrombocytopenia with a median platelet
count of 53 × 109/L (IQR 16-80) and median MPV of 16.3 fL (IQR
15.9 fL-16.4 fL). The median GP1b-V-IX expression was 24.2% (IQR
16.5% - 26.9%) and genetic analysis confirmed BSS in all patients.
3.1.3 | Dense granule deficiency
Dense granule deficiency was diagnosed in 13 patients based on
platelet ADP content below 1.4 μmol/1011 platelets. The median
bleeding score was 10 (IQR 9-14). The median platelet count was
165 × 109/L (IQR 69-303) and in 6/13 patients the platelet count was
below the normal range. The median platelet ADP content was 0.9
μmol/1011 platelets (IQR 0.5-1.2). The LTA results were abnormal in
6/13 patients, but did not reveal a specific pattern. Genetic mutations
were identified in five patients.
3.1.4 | ADP pathway defect
An isolated ADP pathway defect was diagnosed in 22 patients based
on decreased aggregation in response to ADP. A normal aggregation
in response to arachidonic acid differentiates them from patients with
a thromboxane A2 (TxA2) pathway defect (Figure S1A). The median
bleeding score was seven (IQR 5-10). The median aggregation in
response to ADP was 54% (IQR 47% - 61%). Platelet ADP content
was normal in all patients. Genetic mutations were identified in three
patients.
3.1.5 | Thromboxane A2 pathway defect
A TxA2 pathway defect was diagnosed in 15 patients based on
decreased aggregation in response to arachidonic acid (AA), with or
without defective aggregation in response to other agonists (Figure
S1B). The median bleeding score was eight (IQR 5-11). The median
aggregation in response to AA was 10% (IQR 4% - 14 %). Platelet
TABLE 1 Patient characteristics
N = 96
Sex
Women, n (%) 61 (64)
Age
Women, median (IQR) 38 (28–53)
Men, median (IQR) 40 (28-57)
Bleeding score
Women, median (IQR) 9 (7–15)
Men, median (IQR) 6 (3–12)
Type of CPD
ADP pathway defect, n (%) 22 (23)
Bernard-Soulier syndrome, n (%) 4 (4)
Complex abnormalitya, n (%) 6 (6)
Dense granule deficiency, n (%) 13 (14)
Glanzmann thrombasthenia, n (%) 14 (14)
Isolated thrombocytopenia, n (%) 22 (23)
TxA2 pathway defect, n (%) 15 (16)
Abbreviations: CPD, congenital platelet defect; IQR, interquartile range;
TxA2, thromboxane A2.
aComplex abnormality was diagnosed when the patterns of platelet func-
tion defects did not support the diagnosis of a particular type of CPD.
F IGURE 1Bleeding score per
type of congenital platelet defect.






thromboxane A2 [Color figure
can be viewed at
wileyonlinelibrary.com]
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ADP content was normal in all patients. Genetic mutations were iden-
tified in two patients.
3.1.6 | Isolated thrombocytopenia
An isolated thrombocytopenia (IT) was diagnosed in 22 patients based
on a low platelet count, normal platelet function and normal platelet
ADP content. An acquired thrombocytopenia was ruled out based on
negative glycoprotein specific antibodies and thorough anamnesis,
including familiy history and previous treatment for thrombocytope-
nia, with or without response. The median bleeding score was six (IQR
2-10). The median platelet count was 80 × 109/L (IQR 49-126) and
median MPV 9.3 fL (IQR 8.5fL-12.2 fL). Genetic mutations were iden-
tified in two patients.
3.1.7 | Complex abnormalities
A complex abnormality was diagnosed in six patients. A complex
abnormality was diagnosed when the patterns of platelet function
defects in LTA did not support the diagnosis of a particular type of
CPD as described above. The median bleeding score was eight (IQR
4-24). No genetic mutations were identified in this subgroup.
3.2 | Bleeding symptoms in patients with CPDs
Most frequently occurring bleeding symptoms were HMB (49/61,
81% of women), PPH (20/27, 74% of women who gave birth) and
post-operative bleeds (47/73, 64% of patients who underwent sur-
gery) (Figure 2). Rare bleeding symptoms were bleeds from the urinary
tract (4/96, 4%) and CNS bleeds (2/96, 2%).
We classified a bleeding symptom as severe when the domain
score was three or higher. Both CNS bleeds were classified as severe
F IGURE Prevalence of bleeding symptoms in patients with
congenital platelet defects (CPDs). Proportion of CPD patients who
experienced the bleeding symptom (ISTH-BAT domain score ≥ 1).
*Frequencies are based on patients who underwent tooth extraction
(n = 63) or surgery (n = 73). †Frequencies are based on women who
have been menstruating (n = 61) or gave birth (n = 27). CNS, central
nervous system; GI, gastrointestinal; HMB, heavy menstrual bleeding;
PPH, postpartum hemorrhage [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 3Prevalence of (severe) bleeding symptoms and
contribution of bleeding symptoms to the bleeding score. A,
Prevalence of severe bleeding in patients with CPDs. Proportion of
CPD patients who experienced the bleeding symptom and in whom
the bleeding symptom was severe (ISTH-BAT domain score ≥ 3). B,
Contribution of the bleeding symptoms to the bleeding score. The
frequency and severity of the bleeding symptoms are combined to
calculate the contribution of each domain to the sum of all bleeding
scores. C, Prevalence of bleeding symptoms in patients with
Glanzmann and patients with other types of CPDs. Proportion of
Glanzmann patients (solid bars) and patients with other types of CPDs
(striped bars) who experienced the bleeding symptom (ISTH-BAT
domain score ≥ 1). CNS, central nervous system; CPD, congenital
platelet defect; GI, gastrointestinal; HMB, heavy menstrual bleeding;
PPH, postpartum hemorrhage. *Frequencies are based on patients
who underwent tooth extraction or surgery. †Frequencies are based
on women who have been menstruating or gave birth [Color figure
can be viewed at wileyonlinelibrary.com]
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(Figure 3A). Other domains of the ISTH-BAT with a large proportion
of severe bleeds were HMB (47/49, 96% of women who have experi-
enced HMB), post-dental extraction bleeding (31/36, 86% of patients
who experienced bleeding after tooth extraction) and post-operative
bleeding (35/47, 75% of patients who experienced bleeding after sur-
gery). Bleeds from minor wounds were relatively common (50/96,
52%), as were bleeds in the “other” category (42/96, 44%), but these
bleeds were rarely severe: nine of 50 patients (18%) had severe bleeds
from minor wounds, none of 42 patients reported severe “other”
bleeds.
By combining the frequency and severity of the bleeding symp-
toms, the contribution of each domain to the sum of all bleeding
scores can be calculated (Figure 3B). Bleeding symptoms with the
largest contribution to the bleeding score were HMB (19%), post-
operative bleeding (17%), post-dental extraction bleeding (13%) and
epistaxis (12%).
The bleeding score was significantly higher in women than in men
(β 3.5, 95% CI 0.9 to 6.1). When the bleeding score was calculated
without the domains HMB and PPH, there was no significant differ-
ence (β 0.1, 95% CI −2.1 to 2.4).
3.3 | Bleeding symptoms according to type of CPD
Adjusted for age and sex, patients with GT had a significantly higher
bleeding score than patients with other types of CPDs. As compared
to other types of CPDs, GT patients more frequently (P < .01) experi-
enced epistaxis (100% vs 45%), urinary tract bleeds (21% vs 1%), gas-
trointestinal bleeds (50% vs 7%), oral cavity bleeds (71% vs 12%) and
hemarthrosis (36% vs 5%) (Figure 3C). For the other types of CPDs,
the bleeding phenotype was not distinctive. The bleeding phenotypes
of CPDs other than GT were similar.
3.4 | Association between bleeding score and
laboratory measurements
Correlations between the bleeding score and ADP, arachidonic acid
and collagen aggregation were weak to moderate (ρ −0.31, −0.40
and − 0.50 respectively). The bleeding score showed a moderate cor-
relation with the number of abnormal agonists in LTA (ρ 0.45, 95% CI
0.23 to 0.63). When GT patients were not taken into account, the
bleeding score did not correlate with the number of abnormal agonists
in LTA (ρ 0.16, 95% CI −0.10 to 0.42). Also, the bleeding score did not
correlate with a lower platelet ADP content (ρ 0.03, 95% CI −0.19 to
0.25), nor with a lower platelet count (ρ 0.17, 95% CI −0.03 to 0.36).
4 | DISCUSSION
This is the first study to report the bleeding phenotype and diagnostic
characteristics of a large cohort of adult patients with CPDs. Patients
were classified as Glanzmann thrombasthenia, Bernard-Soulier
syndrome, dense granule deficiency, defects in the ADP or thrombox-
ane A2 (TxA2) pathway, isolated thrombocytopenia or complex abnor-
malities. Most frequently occurring bleeding symptoms were HMB,
PPH and post-operative bleeds. Glanzmann thrombasthenia and
female sex were associated with a more severe bleeding phenotype.
The bleeding score was not correlated with the number of abnormal
agonists in LTA, nor with a lower platelet ADP content or lower plate-
let count.
Eighty percent of women reported HMB and in 96% of cases it
was classified as severe. Moreover, HMB accounted for almost 20%
of the sum of all bleeding scores. And, when the bleeding score in
women was calculated without the domains HMB and postpartum
hemorrhage, there was no difference between men and women.
Taken together, this indicates that HMB is a considerable health prob-
lem in women with CPDs. Serious bleeding complications like CNS
bleeds, gastrointestinal bleeds and hemarthrosis were rare, although
more common in patients with GT as compared to other types
of CPDs.
Very few studies described the bleeding phenotype of patients
with CPDs. One previous study in a large cohort of patients with
CPDs showed that epistaxis and cutaneous bleeds most frequently
occurred, and that epistaxis and oral cavity bleeding were the most
severe bleeding symptoms.6 Glanzmann thrombasthenia was widely
represented in their study population (40%) and their study popula-
tion had fewer women included (57%) as compared to ours (64%).
Another previous study reported bleeding scores in a cohort of
patients with CPDs,14 but they did not report on the frequency of
bleeding symptoms. Their study population consisted of mostly chil-
dren and the Pediatric Bleeding Questionnaire was used. One study
reported the bleeding phenotype of patients with Von Willebrand dis-
ease,4 a primary hemostasis defect with similar symptoms. They used
the Tosetto bleeding score15 to assess bleeding symptoms and their
patients most frequently reported HMB, cutaneous bleeds and pro-
longed bleeding from minor wounds.
It is debatable whether the ISTH-BAT is the most suitable tool for
assessing the severity of bleeding symptoms, since domains of the
ISTH-BAT saturate easily. Patients who have experienced a single
bleed after surgery that required DDAVP treatment score the same as
patients with multiple bleeds after surgery that required several trans-
fusions. Also, CNS bleeds are always classified as severe, since the
score is either zero, three or four for that domain. Despite its limita-
tions, the ISTH-BAT is at the moment the best tool to assess bleeding
symptoms, because it takes both the frequency and the severity of
the whole spectrum of bleeding symptoms into account.
In our study, there was a risk for selection bias. Patients with a
clinical suspicion for a CPD were referred for inclusion in the TiN
study and it is likely that the referral rate was higher for patients with
clinically important bleeds, such as HMB or bleeding after a hemo-
static challenge, than for patients with clinically less important bleeds,
such as cutaneous bleeds. This might explain the high prevalence of
these bleeding symptoms in our population. In addition, for some
patients it was not reported whether they had undergone tooth
extraction. When patients reported no bleeding after tooth extraction,
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in 6% of cases it was not reported whether they had undergone tooth
extraction at all. These patients were not included in the analysis for
that domain, which could have led to a slight overestimation of the
prevalence. Also, the ISTH-BAT was not completed at the time of
diagnosis for some patients, but at the time of inclusion in the study.
These patients possibly had more hemostatic challenges, since they
had more time to develop bleeding symptoms, resulting in a higher
bleeding score. Some of these bleeds might have required treatment,
which would also have led to an increase in the bleeding score.
The strength of our study is the inclusion of a large number of
CPD patients. To the best of our knowledge, this is to first study to
evaluate the bleeding phenotype and diagnostic characteristics in a
large cohort of adult patients with various subtypes of CPDs. Insight
into the bleeding phenotype of these patients can lead to better
counseling of patients regarding the prognostic implications of their
bleeding phenotype. It will create more awareness on the clinical pic-
ture of CPDs among doctors and in society. We incorporated explicit
diagnostic criteria for CPDs based on expert opinion. Standardized
diagnostic criteria will reduce under-diagnosis and misdiagnosis in
patients. Moreover, it will allow cluster analysis in patients with similar
phenotypes and further unraveling of the pathophysiology of platelet
defects.
In conclusion, in CPD patients most frequently occuring symp-
toms are HMB and bleeding after a hemostatic challenge. Glanzmann
thrombasthenia and female sex are associated with a more severe
bleeding phenotype.
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